Please ensure Javascript is enabled for purposes of website accessibility

Be Kind to MannKind

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MannKind has good data, but will the FDA approve of it and will diabetics buy it?

I've always wondered what would happen if a drugmaker developed a drug and nobody noticed -- or cared.

I think I just found out.

On Thursday morning, MannKind (NASDAQ:MNKD) announced positive results from its final two phase 3 trials for its inhaled insulin product, Afresa, and its stock ended the day at the exact same price it did the day before. Maybe when the tree falls in the empty forest, it really doesn't make any sound.

After Exubera -- Nektar Therapeutics (NASDAQ:NKTR) and Pfizer's (NYSE:PFE) inhaled insulin product -- was deemed a marketing failure and Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) ditched their programs, investors are rightfully a little worried about the chance of marketing success.

The more immediate question is whether Afresa will even make it to the market -- the drug does have to get past the Food and Drug Administration, after all. I don't think that MannKind has to worry about data about its effectiveness, but the safety-conscious FDA could send it back to the drawing board after it submits its marketing application early next year. There was a higher incidence of lung cancer in patients treated with Exubera versus the control group in a long-term safety analysis and, while MannKind hasn't seen any kind of signal of the same, it's usually easier to prove that something exists than that it doesn't.

With a market cap of $300 million, the risk/reward on MannKind, a Motley Fool Hidden Gems Pay Dirt pick, is looking just about right to me. The company could double from here should it gain marketing approval, and then double or triple again if the drug tops the paltry sales that Pfizer managed with Exubera. That's a lot of reward, but the unpredictable FDA introduces a lot of risk into the equation as well. If you're going to invest, buy carefully on the dips.

More Foolishness on small caps:

Find out why big returns often come in little packages by grabbing a 30-day free trial to Motley Fool Hidden Gems, our small-cap stock recommendation service. 

Novo Nordisk is a Global Gains pick. Pfizer and Eli Lilly are Income Investor selections. Pfizer is also an Inside Value pick, and the Fool owns shares of it. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
$4.17 (-4.14%) $0.18
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$302.62 (0.04%) $0.12
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.72 (0.31%) $0.15
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$104.87 (2.39%) $2.45
Nektar Therapeutics Stock Quote
Nektar Therapeutics
$4.75 (-2.57%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.